


Voltaris5

IN-HOUSE ELECTRON BEAM STERILIZATION

Integrate E-beam sterilization directly into your manufacturing environment to reduce reliance on contract sterilization, simplify product flow, and create the potential for a compelling return on investment.

3–5 MeV | Up to 10 kW | Self-Shielded | In-Line or End-of-Line




BRING STERILIZATION IN-HOUSE. TRANSFORM YOUR SUPPLY CHAIN.


Voltaris5 is a modular, standalone, self-shielded E-beam platform that can be located adjacent to assembly and packaging operations — bringing sterilization directly into the manufacturing environment.

Traditional contract sterilization requires product to move outside the manufacturing operation for sterilization before returning for additional handling and preparation. Bringing sterilization in-house creates a more direct product flow.

TRADITIONAL CONTRACT STERILIZATION ROUTING




Voltaris5 IN-HOUSE STERILIZATION



DISRUPT YOUR SUPPLY CHAIN AND DRAMATICALLY IMPROVE YOUR P&L — WITH THE POTENTIAL FOR PAYBACK IN LESS THAN 3 YEARS*

Choose the right process for the job. There are many situations where contract sterilization is the right approach. There are also medical devices that are ideally suited for low to medium energy in-line self-shielded E-beam treatment. For these applications, ATS has developed the Voltaris5. ATS will validate whether your medical device is suited for E-beam so you can see significant process improvement and ROI.

Voltaris5



Stack up of the internal & external costs and risks associated with the contract sterilization model

BUILDING THE Voltaris5 BUSINESS CASE

The cost of third-party sterilization goes beyond the sterilization service itself. The potential return from in-house, in-line E-beam sterilization depends on product requirements, production volumes and current sterilization costs. The following example illustrates the inputs used to evaluate the opportunity.

How much is reduced lead time to your customer worth?

How could the cost of inventory be reduced by implementing in-line E-beam vs. outsourcing sterilization?

What is it worth to have direct control of your sterilization?

As part of our early engagement, ATS Life Sciences Systems will work with your team to build up the financial return on investment model using current process inputs associated with the internal and external costs of contract sterilization.

ATS Life Sciences Systems also offers a leasing program for 4 and 5 years for the in-line E-beam platform enabling an opex mode versus a capex business model.

READY TO EVALUATE YOUR APPLICATION?

Let's obtain the evidence for technical and commercial feasibility

TEST YOUR PRODUCT(S)	STERILIZATION REQUIREMENTS	PRODUCTION VOLUMES	ROI ANALYSIS
Provide representative product for dosimetry testing. ATS will test your product using 5MeV E-beam in assuring the DUR can be achieved at rate. Align on your quality requirements.	Provide key product characteristics and sterilization requirements including: - Product & package dimensions - Product density/density range - Significant density variations - Minimum sterilization dose - Maximum product tolerance dose	Provide current production requirements, including normal & peak volumes, operating schedule, and anticipated growth, including: - Daily/weekly/monthly volumes - Production days/hours - Extended outage periods - Expected five-year product growth	Work together to develop the ROI for a comparative in-line process vs. outsourcing sterilization.

COULD Voltaris5 MAKE SENSE FOR YOUR OPERATION?

Talk to ATS about evaluating your product, sterilization requirements, production volumes and potential ROI.



[ATSLifeSciences.com](https://www.atslifesciences.com) | lifesciences@atsautomation.com

ATS and the ATS LOGO are trademarks of ATS Corporation and may not be used without permission.

*Illustrative ROI is based on the assumptions presented and will vary by application. Actual results depend on product characteristics, sterilization requirements, production volumes and associated operating and third-party sterilization costs.